Rationale and Design of the Investigation of the Management of Pericarditis (IMPI) Trial: a 2 × 2 Factorial Randomized Double-Blind Multicenter Trial of Adjunctive Prednisolone and Mycobacterium with Immunotherapy in Tuberculous Pericarditis
The primary objective of the IMPI Trial is to assess the effectiveness and safety of prednisolone and M. w immunotherapy in reducing the composite outcome of death, constriction, or cardiac tamponade requiring pericardial drainage in 1,400 patients with TB pericardial effusion.
